Antibiotic Recipe For High Prices: Outcomes Data, Targeted Use
Executive Summary
Drug developers must show value, such as lower death rates, to justify high prices for antibiotics to treat drug resistant organisms, payers note during conference on the Limited Population Antibacterial Drug approval pathway.
You may also be interested in...
Antibiotic Incentive Legislation: Can Reimbursement Horn In?
There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.
Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials
PhRMA working group lays out proposal to allow approval of antibiotics for infections constituting an unmet medical need based on open-label studies and observational data.
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation
FDA and industry are turning their attention to implementation of the Generating Antibiotic Incentives Now provisions of PDUFA V, which include an additional five years of marketing exclusivity for certain products and new guidance aimed at streamlining the drug development process.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: